The Mini-Brain Platform

AxoSim’s new 3D Mini-Brain technology enables human-relevant oligodendrocyte myelination, representing a breakthrough for testing in neurotoxicity and neurodegenerative diseases. This proprietary platform was invented in 2016 by Dr. Thomas Hartung at Johns Hopkins and has been exclusively licensed by AxoSim. Our Mini-Brains recreate a truly biomimetic 3D environment, featuring a unique combination of neurons, astrocytes, and oligodendrocytes.

We deliver human data, faster.

Platform Steps


Begin by differentiating iPSCs into NPCs to create the building blocks for a multi-cellular biomimetic platform. Establish a more phenotypically accurate model.


Differentiate 3D organoids in a proprietary manner to produce three critical cell types: neurons, astrocytes, and oligodendrocytes. Ensure quality and reproducibility through precise control of organoid size to avoid necrotic cores.


Culture organoids to influence cell-cell interaction and induce high levels of myelination. Replicate critical characteristics of neurons and glia and create a better representation of the brain’s structure.


Characterize cellular responses through electrophysiology, ICC, histology, flow cytometry, and gene expression. Correlate phenotypic changes to a drug’s mechanism of action faster and more accurately than currently possible.